We report a case of a 32-year-old Brazilian male, asymptomatic, who underwent an esophagogastroduodenoscopy in July 2014, which revealed a friable exophytic lesion in the esophagogastric junction (EGJ), Siewert 1. The biopsy of the lesion showed a well-differentiated intestinal-type adenocarcinoma, HER2 negative. The patient received neoadjuvant chemoradiotherapy with Carboplatin and Paclitaxel, followed by a distal esophagectomy and gastrectomy with extended D2 lymph node dissection. A partial pathological response (ypT2pN0) was obtained. Surveillance was initiated. In May 2016, a Computerized Tomography (CT) revealed suspicious hepatic nodules, which were confirmed as metastasis from gastric cancer by liver biopsy. He underwent first-line chemotherapy with mFOLFOX6, but the oxaliplatin was suspended after twelve cycles due to limiting peripheral neuropathy. There was observed hepatic disease progression after twenty four cycles with 5-Fluoracil .The treatment was then modified to FOLFIRI, resulting in progressive disease after 4 cycles. Due to limitations stemming from the public healthcare service and to prior toxicity, a decision to employ mFOLFOX6 intra-arterial infusion was made. The patient had a good response to the treatment, with no significant toxicity. In July 2018, a hepatic embolization was performed, followed by hepatic segmentectomy (segments VI, VII and VIII). At two years’ follow-up, the patient is alive and with no evidence of recurrence.